
Opinion|Videos|December 15, 2023
LOTIS-2 Trial: Loncastuximab Tesirine for R/R DLBCL
Author(s)Matthew A. Lunning, DO, FACP
Dr. Lunning, an expert in lymphoma, discusses the results and clinical significance of the LOTIS-2 trial, evaluating loncastuximab tesirine for patients with R/R DLBCL.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dual BCMA/CD19 CAR T, AZD0120, Yields 96% ORR in Myeloma; Fast Turnaround
2
Linvoseltamab Monotherapy Effective in Newly Diagnosed Multiple Myeloma
3
NCCN Guidelines in nccRCC Weigh New Data for Combinations
4
Subcutaneous Cevostamab Shows Early Promise in R/R Myeloma
5








































